$MREO Hope BP is realizing the longer they let Mereo go unpurchased, the more news is dropped and value is being added by the week. What was once a fair price for a BO last week is no longer today..

$MREO good couple millies, sixteen hundred

$MREO Etigilimab #tigit will attract multiple bidders. $NVS the front runner $ITOS $GSK fully committed in #TIGIT nugget in today 3rd qtr earnings “Furthermore, we remain encouraged that the belrestotug + dostarlimab doublet represents a high quality TIGIT:PD-1 combination.

#TIGIT 🔥🔥🔥 $MREO new 52 week high. 📈

$MREO BOOM !! I've been covering the entire breakout for members.

Department of super weird trivia: On Black Monday in 1987, the CEO of the WSJ's parent company was meeting with two Wall Street bankers who were advising on some financial transaction. One of the bankers was Gary Gensler. The other was Jay Powell. sec.gov/news/speech/ge…

$MREO I can't believe the stock is trading $2.05. OncXerna Partnership could be valued $300-$500M if OncXerna gets acquired unbelievable Mereo partner OncXerna developing Artificial intelligence powers precision cancer medicine -OncXerna Creating a biomarker #AI platform

$MREO OncXerna 👍 its ridiculous the stock continues to trade $2s Cathie Wood ARK Invest 3 Favorite AI Stocks: October 2023. $ZM $EXAS $PATH -Exact Sciences (EXAS): The firm is leveraging AI partnerships to improve cancer screening. -Exact Sciences’ AI potential

$MREO BO price target $8-$10 is bargain for big pharmas. I still strongly believe the company pipeline is worth a lot more than $10 ? How Underappreciated and Undervalued Diversified late-stage pipeline: 6 clinical assets which are unheard of for company trading $1.95

Mereo Biopharma Group plc - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Commission File Number: 001- - 6-K - December 18, 202s $MREO USA company now. The FOR SALE sign officially up fintel.io/doc/sec-mereo-…

$MREO

$MREO 🤔 I watched yesterday the CNBC Interview with Novartis CEO "Our overall M&A strategy is really to focus on sub $5 billion assets," Novartis CEO Vasant Narasimhan said in an interview on CNBC. We made 15 deals last year sub $3Bn $NVS terminated last year $2.7Bn

$MREO Been a long time

$MREO WOW THIS IS BIG the rumor have been confirmed that Onxcerna Therapeutics is in process being sold $MREO will reeive $300M milestone payment who ever acquired Onxcerna Therapeutics OncXerna Therapeutics CFO confirmed the rumor "things were great while I was there but

$INBX — $SNY, $XBI $MREO $INBX sells their AATD candidate, INBRX-101, to $SNY for up to $2.2b — $30 per share in cash, $5 CVR, and .25 share in New Inhibrx. Should serve as point of comparison for potential value of $MREO Alvelestat in AATD, a candidate at similar clinical

$MREO Current market cap $471M: IMO BUY OUT PRICE MINIMUM $2BN / $15 LEAD ASSET POTENTIAL VALUATION Alvelestat phase 3 ready #AATD VALUE $1.5b - $2.bn similar to $INBX INBRX-101 acquired for $2.2Bn Setrusumab- Osteogenesis Imperfecta bone disease value +$1Bn - similar

$MREO - This needs to sink in here on how good Setrusumab is. 20 of 24 patients no fractures after 6 months and one of 1st patients on Setru walking after 17 months and likely update coming as he will be on Setru almost 2 years soon. Will be SOC in OI....

$MREO BO leak or what here

Cantor today's news from $INSM has positive read for $MREO's second lead asset, alvelestat, a neutrophil elastase inhibitor in pre-Phase 3 development for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. 3 reasons given